WSURF Case 610
Bioactive Lipid Based Approach for Enhancement of Cancer (e.g. Ovarian) Chemotherapy Treatment
Summary
Currently the major treatment for cancer is chemotherapy after surgery de-bulk. One of the major problems is tumor chemotherapy resistance. This invention is a combined adjunct treatment using bioactive lipids with chemotherapy to reduce chemo-resistance and make the therapy more efficient.
The mixture will include 1) chemotherapy (e.g. carboplatin); 2) Bioactive lipid analogs that are antagonists for growth promoting receptors; 3) signal transduction antagonists for pathways such as the P13Kact and MAPK and/or 4) Bioactive Lipid analogs that specifically promote the apoptosis pathway. Modifications include different combination and agents and chemotherapeutics.
Applications & Advantages
- The invention is directed toward inhibiting growth and/or killing cancer cells by modulating the PI3K signal transduction pathway, and using additional therapeutic agents, such as triptolide (TPL), a diterpenoid triexposide purified from a Chinese herb Tripterygium Wilfordii Hook F (or the acronym:TWHF)
IP Status
The technology is protected by a PCT application and is available for exclusive worldwide licensing.
For more information about this technology please contact WSURF:
1610 NE Eastgate Blvd, Suite 650
Pullman, WA 99164
Phone: (509) 335-5526
Fax: (509) 335-7237
wsurf@wsu.edu
